
Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …

AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …

Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia

